182 related articles for article (PubMed ID: 38634473)
1. Reducing neonatal Fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-β antibody.
Schlein E; Andersson KG; Dallas T; Syvänen S; Sehlin D
MAbs; 2024; 16(1):2339337. PubMed ID: 38634473
[TBL] [Abstract][Full Text] [Related]
2. ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer's disease with a bispecific, brain-penetrating fusion protein.
Bonvicini G; Syvänen S; Andersson KG; Haaparanta-Solin M; López-Picón F; Sehlin D
Transl Neurodegener; 2022 Dec; 11(1):55. PubMed ID: 36567338
[TBL] [Abstract][Full Text] [Related]
3. Brain pharmacokinetics of mono- and bispecific amyloid-β antibodies in wild-type and Alzheimer's disease mice measured by high cut-off microdialysis.
Julku U; Xiong M; Wik E; Roshanbin S; Sehlin D; Syvänen S
Fluids Barriers CNS; 2022 Dec; 19(1):99. PubMed ID: 36510227
[TBL] [Abstract][Full Text] [Related]
4. A bispecific Tribody PET radioligand for visualization of amyloid-beta protofibrils - a new concept for neuroimaging.
Syvänen S; Fang XT; Hultqvist G; Meier SR; Lannfelt L; Sehlin D
Neuroimage; 2017 Mar; 148():55-63. PubMed ID: 28069541
[TBL] [Abstract][Full Text] [Related]
5. Brain delivery of biologics using a cross-species reactive transferrin receptor 1 VNAR shuttle.
Sehlin D; Stocki P; Gustavsson T; Hultqvist G; Walsh FS; Rutkowski JL; Syvänen S
FASEB J; 2020 Oct; 34(10):13272-13283. PubMed ID: 32779267
[TBL] [Abstract][Full Text] [Related]
6. High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain.
Fang XT; Hultqvist G; Meier SR; Antoni G; Sehlin D; Syvänen S
Neuroimage; 2019 Jan; 184():881-888. PubMed ID: 30300753
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, biodistribution and brain retention of a bispecific antibody-based PET radioligand for imaging of amyloid-β.
Sehlin D; Fang XT; Meier SR; Jansson M; Syvänen S
Sci Rep; 2017 Dec; 7(1):17254. PubMed ID: 29222502
[TBL] [Abstract][Full Text] [Related]
8. Disaggregation of amyloid plaque in brain of Alzheimer's disease transgenic mice with daily subcutaneous administration of a tetravalent bispecific antibody that targets the transferrin receptor and the Abeta amyloid peptide.
Sumbria RK; Hui EK; Lu JZ; Boado RJ; Pardridge WM
Mol Pharm; 2013 Sep; 10(9):3507-13. PubMed ID: 23924247
[TBL] [Abstract][Full Text] [Related]
9. Pinpointing Brain TREM2 Levels in Two Mouse Models of Alzheimer's Disease.
Meier SR; Sehlin D; Hultqvist G; Syvänen S
Mol Imaging Biol; 2021 Oct; 23(5):665-675. PubMed ID: 33620643
[TBL] [Abstract][Full Text] [Related]
10. Age, dose, and binding to TfR on blood cells influence brain delivery of a TfR-transported antibody.
Faresjö R; Sehlin D; Syvänen S
Fluids Barriers CNS; 2023 May; 20(1):34. PubMed ID: 37170266
[TBL] [Abstract][Full Text] [Related]
11. A Brain-Targeting Bispecific-Multivalent Antibody Clears Soluble Amyloid-Beta Aggregates in Alzheimer's Disease Mice.
Rofo F; Meier SR; Metzendorf NG; Morrison JI; Petrovic A; Syvänen S; Sehlin D; Hultqvist G
Neurotherapeutics; 2022 Sep; 19(5):1588-1602. PubMed ID: 35939261
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of immunotherapy with a brain penetrating Aβ antibody in a mouse model of Alzheimer's disease.
Gustavsson T; Metzendorf NG; Wik E; Roshanbin S; Julku U; Chourlia A; Nilsson P; Andersson KG; Laudon H; Hultqvist G; Syvänen S; Sehlin D
Alzheimers Res Ther; 2023 May; 15(1):90. PubMed ID: 37131196
[TBL] [Abstract][Full Text] [Related]
13. SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-β antibody in a mouse model of Alzheimer's disease.
Gustavsson T; Syvänen S; O'Callaghan P; Sehlin D
Transl Neurodegener; 2020 Sep; 9(1):37. PubMed ID: 32951598
[TBL] [Abstract][Full Text] [Related]
14. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor.
Deane R; Sagare A; Hamm K; Parisi M; LaRue B; Guo H; Wu Z; Holtzman DM; Zlokovic BV
J Neurosci; 2005 Dec; 25(50):11495-503. PubMed ID: 16354907
[TBL] [Abstract][Full Text] [Related]
15. Efficient clearance of Aβ protofibrils in AβPP-transgenic mice treated with a brain-penetrating bifunctional antibody.
Syvänen S; Hultqvist G; Gustavsson T; Gumucio A; Laudon H; Söderberg L; Ingelsson M; Lannfelt L; Sehlin D
Alzheimers Res Ther; 2018 May; 10(1):49. PubMed ID: 29793530
[TBL] [Abstract][Full Text] [Related]
16. Advancing
Wuensche TE; Stergiou N; Mes I; Verlaan M; Schreurs M; Kooijman EJM; Janssen B; Windhorst AD; Jensen A; Asuni AA; Bang-Andersen B; Beaino W; Dongen GAMS; Vugts DJ
Theranostics; 2022; 12(16):7067-7079. PubMed ID: 36276653
[TBL] [Abstract][Full Text] [Related]
17. Fusion of hIgG1-Fc to 111In-anti-amyloid single domain antibody fragment VHH-pa2H prolongs blood residential time in APP/PS1 mice but does not increase brain uptake.
Rotman M; Welling MM; van den Boogaard ML; Moursel LG; van der Graaf LM; van Buchem MA; van der Maarel SM; van der Weerd L
Nucl Med Biol; 2015 Aug; 42(8):695-702. PubMed ID: 25960433
[TBL] [Abstract][Full Text] [Related]
18. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target.
Yu YJ; Zhang Y; Kenrick M; Hoyte K; Luk W; Lu Y; Atwal J; Elliott JM; Prabhu S; Watts RJ; Dennis MS
Sci Transl Med; 2011 May; 3(84):84ra44. PubMed ID: 21613623
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates.
Yu YJ; Atwal JK; Zhang Y; Tong RK; Wildsmith KR; Tan C; Bien-Ly N; Hersom M; Maloney JA; Meilandt WJ; Bumbaca D; Gadkar K; Hoyte K; Luk W; Lu Y; Ernst JA; Scearce-Levie K; Couch JA; Dennis MS; Watts RJ
Sci Transl Med; 2014 Nov; 6(261):261ra154. PubMed ID: 25378646
[TBL] [Abstract][Full Text] [Related]
20. Functionalization of Radiolabeled Antibodies to Enhance Peripheral Clearance for High Contrast Brain Imaging.
Schlein E; Syvänen S; Rokka J; Gustavsson T; Rossin R; Robillard M; Eriksson J; Sehlin D
Mol Pharm; 2022 Nov; 19(11):4111-4122. PubMed ID: 36201682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
